Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05973825
Other study ID # ONZ-2023-0154
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2024
Est. completion date July 12, 2029

Study information

Verified date April 2024
Source University Hospital, Ghent
Contact Linos Vandekerckhove
Phone +3293323398
Email linos.vandekerckhove@ugent.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a dual arm (arm 1 and arm 2) multi-centric non-randomized (prospective) study. Two new multicentric cohorts will be set up in 4 Belgian HIV reference centers (UZ Gent, UZ Brussel, University Hospital Liege and St. Pierre Hospital Brussels): cohort 1 will comprise PLWH in whom ART was initiated during acute HIV infection minimum 3 years ago but no more than 10 years ago (short-term ART cohort); cohort 2 will comprise PLWH on ART since >20 years (long-term ART cohort). Participants will be included based on suppressed viremia and uninterrupted ART since initiation. Participants will undergo one blood sampling and one leukapheresis. In and exclusion criteria are described below.


Description:

This project aims to gain new knowledge and insights into the viral reservoir establishment and HIV Latency as well as to develop new powerful tools to study latency reversal, that will ultimately contribute to research into an HIV curative treatment. The study objectives are - To collect and store state of the art peripheral blood samples (60 vials of 50 X106 PBMC's) from two patient cohorts, 10 acute seroconverters and 10 long-term ART-treated patients . - To characterize and compare the latent reservoir in blood samples from both cohorts as for the proviral genome, transcriptome, epigenome and T cell receptor level - To perform an immunological profiling of infected cells. - To evaluate available drugs that induce either a block-and-lock or a shock-and-kill in in vitro interventions using blood samples from both cohorts - To accelerate the negative selection of transcriptionally competent proviruses in vitro and determine the role of the different determinants. - To make all data available for the different partners and integrate all data acquired.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 24
Est. completion date July 12, 2029
Est. primary completion date July 12, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: Cohort 1: short-term ART cohort - Documented HIV-1 infection - Able and willing to provide written informed consent - Age = or >18 years and < 80 years - ART started during a documented recent HIV-1 infection (acute HIV infection, defined as: - Clinical symptoms of acute seroconversion and incomplete Western Blot, or - Negative screening test within the past 6 months and incomplete Western Blot, or - Risk contact within the <3 months and presumable primo-infection with or without clinical symptoms and incomplete Western Blot. - Being on ART since minimum 2 years and maximum 10 years - Participants should have had a routine plasma viral load measurement at least once a year. - Viral load < 40 or <50 copies/ml determined by the assay (used in the local centers) for at least 3 years (one blip < 200 copies/ml is allowed) - Ability and willingness to have blood samples collected and stored for 20 years and used for various research purposes. - Patients with HIV-1 subtype B are preferred for inclusion (as most of the complex assays are subtype B specific). However, if the investigators do not reach our target of 10 participants, patients infected with other subtypes will be allowed to enter the study. (Primers will subsequently be adapted to the patient-specific proviral sequences). Cohort 2: long-term ART cohort - Documented HIV-1 infection - Able and willing to provide written informed consent - Age = or >18 years and < 80 years - Being on ART since at least 20 years - ART should not have been started during a documented recent HIV-1 infection (acute HIV infection), defined as: - Clinical symptoms of acute seroconversion and incomplete Western Blot or - Negative screening test within the past 6 months and incomplete Western Blot or - Risk contact within <3 months and presumable primo-infection with or without clinical symptoms and incomplete Western Blot. - Patients should have had a routine plasma viral load measurement at least once a year. - Routine plasma viral load < 40 or <50 copies/ml determined by the assay used in the local centres for at least 20 years (one blip < 200 copies/ml is allowed if it occurred >10 years ago) - Ability and willingness to have blood samples collected and stored for 20 years and used for various research purposes. - Participants with HIV-1 subtype B are preferred for inclusion (as most of the complex assays are subtype B specific). However, if the investigators do not reach our target of 10 participants, patients infected with other subtypes will be allowed to enter the study. (Primers will subsequently be adapted to the patient-specific proviral sequences). Exclusion Criteria: - Previous or current history of opportunistic infection (AIDS defining events as defined in category C of the Centers for Disease Control and Prevention (CDC) clinical classification), consisting of chronic HIV-1 infection. - Evidence of active Hepatitis B-virus (HBV) infection (Hepatitis B surface antigen positive or HBV viral load positive in the past and no evidence of subsequent seroconversion (= HBV antigen or viral load negative and positive HBV surface antibody). - Evidence of active HCV infection (HCV antibody positive result within 60 days prior to study entry with positive HCV viral load or, if the HCV antibody result is negative, a positive HCV RNA result within 60 days prior to study entry). - Current or known history of cardiomyopathy or significant ischemic or cerebrovascular disease. - Current cancer. - History of HIV-related thrombocytopenia. - Pregnancy or breastfeeding. - Any condition, including preexisting psychiatric and psychological disorders, which will in the opinion of the investigator interfere with the trial conduct or safety of the participant. - Abnormal results of standard of care laboratory tests: 1. Confirmed haemoglobin <11g/dl for women and <12 g/dl for men 2. Confirmed platelet count <100 000/µl * 3. Confirmed neutrophil count <1000/µl 4. Confirmed Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)>10x upper limit of normal (ULN) - Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements. - Acute or serious illness, in the opinion of the site investigator, requiring systemic treatment and/or hospitalization within 60 days prior to entry.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Leucapheresis
leucapheresis is a procedure in which a large amount of blood cells are obtained by an apheresis procedure

Locations

Country Name City State
Belgium UZ Gent Gent Oost-Vlaanderen

Sponsors (7)

Lead Sponsor Collaborator
University Hospital, Ghent Centre Hospitalier Universitaire de Liege, Centre Hospitalier Universitaire Saint Pierre, KU Leuven, Universitair Ziekenhuis Brussel, Université Libre de Bruxelles, Vrije Universiteit Brussel

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Information on virological aspects of people on long term ART versus people treated during recent infection Intact proviral deoxyribonucleic acid (DNA) assay quantified by digital Polymerase Chain Reaction (pcr) 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT03940521 - Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
Completed NCT03227731 - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women Phase 2/Phase 3
Completed NCT03570918 - MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy Phase 1
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Active, not recruiting NCT04022967 - ANRS 12372 MODERATO Study Phase 3
Not yet recruiting NCT06282783 - Studying Topiramate for Re-Activating the HIV-1 Reservoir Phase 1/Phase 2
Not yet recruiting NCT06337032 - A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments Phase 4
Completed NCT04711265 - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Recruiting NCT03536234 - Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients Phase 2
Completed NCT04340388 - Contribution of Dolutegravir to Obesity and Cardiovascular Disease Phase 4
Withdrawn NCT05769569 - Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission Phase 1
Enrolling by invitation NCT05584397 - Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
Completed NCT04963712 - Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder Early Phase 1
Completed NCT04388904 - Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART) Phase 4
Not yet recruiting NCT04894357 - Impact of V106I on Resistance to Doravirine
Not yet recruiting NCT04311957 - Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults Phase 4
Not yet recruiting NCT04311944 - Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD N/A
Not yet recruiting NCT04513496 - Telemedicine in HIV Care in Buenos Aires
Completed NCT04568239 - Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
Completed NCT03998176 - Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE Phase 4